Ken Griffin Outlook Therapeutics, Inc. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.2 - $1.78 $2,703 - $24,060	13,517 New	13,517 $2,000
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $49,430 - $66,730	49,430 Added 119.9%	90,657 $98,000
Q4 2022 Feb 14, 2023	BUY	$0.87 - $1.33 $7,330 - $11,206	8,426 Added 25.69%	41,227 $44,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $22,676 - $28,012	22,232 Added 210.35%	32,801 $40,000
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $58,158 - $128,459	-63,910 Reduced 85.81%	10,569 $11,000

Q1 2022 May 16, 2022	SELL	$1.22 - $2.03 $4,035 - $6,715	-3,308 Reduced 4.25%	74,479 $133,000
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.23 $59,325 - $104,169	-46,713 Reduced 37.52%	77,787 $105,000
Q3 2021 Nov 15, 2021	BUY	$2.12 - $2.76 $102,103 - $132,927	48,162 Added 63.09%	124,500 $270,000
Q2 2021 Aug 16, 2021	SELL	$1.78 - $2.76 $178,042 - $276,066	-100,024 Reduced 56.72%	76,338 $190,000
Q1 2021 May 17, 2021	BUY	$0.94 - $3.31 $83,598 - $294,374	88,935 Added 101.72%	176,362 $397,000
Q4 2020 Feb 16, 2021	BUY	$0.7 - $1.58 $61,198 - $138,134	87,427 New	87,427 $114,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.66B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.